INTERCEPT PHARMACEUTICALS, INC. Contracts & Agreements

Third Supplemental Indenture, dated as of November 8, 2023, between Intercept Pharmaceuticals, Inc., and U.S. Bank Trust Company, National Association (Filed With SEC on November 8, 2023)

Second Supplemental Indenture, dated as of November 8, 2023, between Intercept Pharmaceuticals, Inc. and U.S. Bank Trust Company, National Association (Filed With SEC on November 8, 2023)

Agreement and Plan of Merger, dated September 26, 2023, among Intercept Pharmaceuticals, Inc., Alfasigma S.p.A. and Interstellar Acquisition Inc (Filed With SEC on September 26, 2023)

2023 Equity Incentive Plan (Filed With SEC on August 2, 2023)

Amendment to the Agreement for the Supply of Manufactured Products, dated May 15, 2023, between Intercept Pharma Europe Ltd. and Amdipharm Ltd (Filed With SEC on May 18, 2023)

Sales Agreement dated March 24, 2023 (Filed With SEC on March 24, 2023)

Description of Securities of the Registrant (Filed With SEC on March 2, 2023)

Form of Exchange Agreement for the 2026 Notes (Filed With SEC on August 19, 2022)

Share Purchase Agreement, dated May 5, 2022, between Intercept Pharmaceuticals, Inc. (ICPT Inc.) as seller and Mercury Pharma Group Limited (Mercury Pharma) as purchaser (Filed With SEC on August 3, 2022)

Sublicense Agreement, dated May 5, 2022, among Intercept Pharma Europe Ltd. (IPEL), Mercury Pharma, and ICPT Inc (Filed With SEC on August 3, 2022)

Agreement for the Supply of Manufactured Products, dated May 5, 2022, between IPEL and Amdipharm Limited (Amdipharm) (Filed With SEC on August 3, 2022)

Business Transfer Agreement, dated May 5, 2022, between IPEL and Advanz Pharma Services (UK) Limited (Advanz Services) (Filed With SEC on August 3, 2022)

Safety Data Exchange Agreement, dated May 5, 2022, between ICPT Inc. and Mercury Pharma (Filed With SEC on August 3, 2022)

Transitional Services Agreement, dated May 5, 2022, between ICPT Inc. and Advanz Services (Filed With SEC on August 3, 2022)

Master Trademark Assignment Agreement, dated May 5, 2022, by and among ICPT Inc., RXF Technologies, Inc. and Mercury Pharma (Filed With SEC on August 3, 2022)

Amendment to Transitional Services Agreement, dated July 26, 2022, between ICPT Inc. and Advanz Services (Filed With SEC on August 3, 2022)

Amendment to Safety Data Exchange Agreement, dated July 1, 2022, between ICPT Inc. and Mercury Pharma (Filed With SEC on August 3, 2022)

Amendment to Share Purchase Agreement, dated July 1, 2022, between ICPT Inc. and Mercury Pharma (Filed With SEC on August 3, 2022)

Intercept Pharmaceuticals, Inc. Amended and Restated Equity Incentive Plan (Filed With SEC on August 3, 2022)

Form of Stock Option Grant Notice and Agreement for Employees and Consultants (Filed With SEC on August 3, 2022)

Form of Stock Option Grant Notice and Agreement for Directors (Filed With SEC on August 3, 2022)

Form of Restricted Stock Unit Award Grant Notice and Agreement for Employees and Consultants (Filed With SEC on August 3, 2022)

Form of Restricted Stock Unit Award Grant Notice and Agreement for Directors (Filed With SEC on August 3, 2022)

Form of Performance Stock Unit Grant Notice and Agreement (Filed With SEC on August 3, 2022)

Employment Agreement, effective April 21, 2022, between the Registrant and Rocco Venezia (Filed With SEC on May 6, 2022)

Description of Securities of the Registrant (Filed With SEC on March 2, 2022)

Agreement of Lease, dated February 7, 2022, between United States Fire Insurance Company as Landlord and Intercept Pharmaceuticals, Inc., as Tenant (Filed With SEC on February 9, 2022)

2022 Cash Incentive Plan (Filed With SEC on January 31, 2022)

2022 Cash Incentive Plan - Form of Performance-Based Award Agreement (Filed With SEC on January 31, 2022)

Indenture, dated as of August 17, 2021, between Intercept Pharmaceuticals, Inc. and U.S. Bank National Association, as trustee (Filed With SEC on August 23, 2021)

First Supplemental Indenture, dated as of August 17, 2021, between Intercept Pharmaceuticals, Inc. and U.S. Bank National Association, as trustee and as collateral agent (Filed With SEC on August 23, 2021)

Security Agreement, dated as of August 17, 2021, among Intercept Pharmaceuticals, Inc., the Guarantors that may from time to time be a party thereto and U.S. Bank National... (Filed With SEC on August 23, 2021)

Employment Agreement, effective May 17, 2021, between the Registrant and Andrew Saik (Filed With SEC on July 29, 2021)

Employment Agreement, effective June 2, 2021, between the Registrant and M. Michelle Berrey (Filed With SEC on July 29, 2021)

Employment Agreement, effective January 4, 2021, between the Registrant and Bryan Ball (Filed With SEC on May 6, 2021)

Employment Agreement, effective February 9, 2021, between the Registrant and Lisa DeFrancesco (Filed With SEC on May 6, 2021)

Employment Agreement, effective February 15, 2021, between the Registrant and Linda Richardson (Filed With SEC on May 6, 2021)

Description of Securities of the Registrant (Filed With SEC on February 25, 2021)

Employment Agreement, effective as of December 18, 2020, between the Registrant and Jared Freedberg (Filed With SEC on February 25, 2021)

Commercial Manufacturing and Supply Agreement, dated August 12, 2016, between the Registrant and PharmaZell GMBH (Filed With SEC on February 25, 2021)

Sumitomo Agreement, dated March 29, 2011, between the Registrant and Sumitomo Dainippon Pharma Co., Ltd (Filed With SEC on February 25, 2021)

Amended and Restated Employment Agreement by and between Intercept Pharmaceuticals, Inc. and Jerome Durso, dated December 9, 2020 (Filed With SEC on December 10, 2020)

Retirement and Consulting Agreement by and between Intercept Pharmaceuticals, Inc. and Mark Pruzanski, M.D., dated December 9, 2020 (Filed With SEC on December 10, 2020)

Form of Stock Option Grant Notice and Agreement for Directors (Filed With SEC on August 10, 2020)

Form of Restricted Stock Unit Award Grant Notice and Agreement for Directors (Filed With SEC on August 10, 2020)

Employment Agreement, effective June 20, 2015, between the Registrant and Richard Kim (Filed With SEC on August 10, 2020)

Description of Securities of the Registrant (Filed With SEC on February 25, 2020)

Form of Stock Option Grant Notice and Agreement for Employees and Consultants (Filed With SEC on February 25, 2020)

Form of Restricted Stock Unit Award Grant Notice and Agreement for Employees and Consultants (Filed With SEC on February 25, 2020)

Form of Performance Stock Unit Grant Notice and Agreement (Filed With SEC on February 25, 2020)

Employment Agreement, effective November 19, 2019, between the Registrant and Jason Campagna (Filed With SEC on February 25, 2020)

Letter Agreement, dated October 25, 2019, between the Registrant and Sumitomo Dainippon Pharma Co., Ltd (Filed With SEC on February 25, 2020)

Third Amendment to Lease, dated November 1, 2019, between the Registrant and Legacy Yards Tenant LP (Filed With SEC on November 5, 2019)

Employment Agreement, effective January 22, 2018, between the Registrant and Ryan Sullivan (Filed With SEC on August 8, 2019)

Employment Agreement, effective February 6, 2018, between the Registrant and Gail Cawkwell (Filed With SEC on August 8, 2019)

Common Stock Underwriting Agreement, dated May 9, 2019, between Intercept Pharmaceuticals, Inc. and Goldman Sachs & Co. LLC, Credit Suisse Securities (USA) LLC and Jefferies LLC,... (Filed With SEC on May 14, 2019)

Convertible Notes Underwriting Agreement, dated May 9, 2019, between Intercept Pharmaceuticals, Inc. and Goldman Sachs & Co. LLC, Credit Suisse Securities (USA) LLC and Jefferies... (Filed With SEC on May 14, 2019)

Securities Purchase Agreement, dated May 8, 2019, between Intercept Pharmaceuticals, Inc. and Samsara BioCapital, L.P (Filed With SEC on May 14, 2019)

Second Supplemental Indenture, dated as of May 14, 2019, between Intercept Pharmaceuticals, Inc. and U.S. Bank National Association, as Trustee (including the form of 2.00%... (Filed With SEC on May 14, 2019)

Form of Stock Option Grant Notice and Agreement for Employees and Consultants (Filed With SEC on May 8, 2019)

Form of Restricted Stock Unit Grant Notice and Agreement for Employees and Consultants (Filed With SEC on May 8, 2019)

Form of Performance Stock Unit Grant Notice and Agreement (Filed With SEC on May 8, 2019)

Fourth Amendment to Lease, dated as of October 30, 2018, between the Registrant and Irvine Eastgate Office II LLC (Filed With SEC on November 1, 2018)

Third Amendment to Lease, dated as of June 21, 2018, between the Registrant and Irvine Eastgate Office II LLC (Filed With SEC on August 7, 2018)

Second Amendment to Lease, dated as of June 22, 2018, between the Registrant and Legacy Yards Tenant LP (Filed With SEC on August 7, 2018)

Amendment No. 1, dated as of June 8, 2011, to that certain License Agreement, dated March 29, 2011, between the Registrant and Sumitomo Dainippon Pharma Co., Ltd (Filed With SEC on May 10, 2018)

Amendment No. 2, dated as of September 16, 2011, to that certain License Agreement, dated March 29, 2011, between the Registrant and Sumitomo Dainippon Pharma Co., Ltd (Filed With SEC on May 10, 2018)

Amendment No. 3, dated as of February 13, 2018, to that certain License Agreement, dated March 29, 2011, between the Registrant and Sumitomo Dainippon Pharma Co., Ltd (Filed With SEC on May 10, 2018)

Form of Performance Stock Unit Grant Notice and Agreement (Filed With SEC on May 10, 2018)

Form of Performance Share Grant Notice and Agreement (Filed With SEC on May 10, 2018)

Underwriting Agreement, dated April 5, 2018, between Intercept Pharmaceuticals, Inc. and Credit Suisse Securities (USA) LLC and Jefferies LLC (Filed With SEC on April 10, 2018)

Securities Purchase Agreement, dated April 4, 2018, between Intercept Pharmaceuticals, Inc. and the purchasers named therein (Filed With SEC on April 10, 2018)

Amendment #1 to Manufacturing and Supply Agreement by and between the Registrant and PharmaZell GMBH, dated December 12, 2017 (Filed With SEC on February 28, 2018)

Separation Agreement by and between the Registrant and Rachel McMinn, effective as of December 31, 2017 (Filed With SEC on February 28, 2018)

Termination of Lease between Hudson Yards Owner LLC and the Registrant, dated December 31, 2017 (Filed With SEC on February 28, 2018)

Employment Agreement by and between Intercept Pharmaceuticals, Inc. and Christian Weyer, effective as of November 27, 2017 (Filed With SEC on December 1, 2017)

Employment Agreement by and between Intercept Pharmaceuticals, Inc. and David Shapiro, effective as of November 27, 2017 (Filed With SEC on December 1, 2017)

First Amendment to Lease Agreement between Legacy Yards Tenant LP and the Registrant, dated as of June 27, 2017 (Filed With SEC on November 6, 2017)

EMPLOYMENT AGREEMENT (Filed With SEC on August 3, 2017)

EMPLOYMENT AGREEMENT (Filed With SEC on May 10, 2017)

DATED: 7th October 2016 (1) INTERCEPT PHARMA EUROPE LTD and (2) LISA BRIGHT MORRISON (Filed With SEC on March 1, 2017)

LEGACY YARDS TENANT LP, Landlord TO INTERCEPT PHARMACEUTICALS, INC., Tenant (Filed With SEC on March 1, 2017)

ONE HUDSON YARDS OWNER LLC, Landlord TO INTERCEPT PHARMACEUTICALS, INC., Tenant (Filed With SEC on March 1, 2017)

SECOND AMENDMENT TO LEASE (Filed With SEC on November 9, 2016)

Confidential Materials omitted and filed separately with the Securities and Exchange Commission. Double asterisks denote omissions. (Filed With SEC on November 9, 2016)

EMPLOYMENT AGREEMENT (Filed With SEC on August 9, 2016)

INVENTION, NON-DISCLOSURE,NON-COMPETITION AND NON-SOLICITATIONAGREEMENT (Filed With SEC on August 9, 2016)

[Remainder of Page Intentionally Left Blank;Signature Page Follows] (Filed With SEC on August 9, 2016)

INTERCEPT PHARMACEUTICALS, INC. (a Delaware corporation) $400,000,000 3.25% Convertible Senior Notes due 2023 UNDERWRITING AGREEMENT (Filed With SEC on July 6, 2016)

INTERCEPTPharmaceuticals, Inc. and U.S.Bank National Association, as Trustee INDENTURE Dated as of July 6, 2016 SENIOR DEBT SECURITIES (Filed With SEC on July 6, 2016)

INTERCEPT PHARMACEUTICALS, INC. AND U.S. BANK NATIONAL ASSOCIATION, as Trustee FIRST SUPPLEMENTAL INDENTURE Dated as of July 6, 2016 to Indenture for Senior Debt Securities Dated... (Filed With SEC on July 6, 2016)

Annex A RELEASEOF CLAIMS1 (Filed With SEC on May 10, 2016)

DATED 22 January 2016 PERFORMING RIGHT SOCIETY, LIMITED as Landlord and INTERCEPT PHARMA EUROPE LTD as Tenant and INTERCEPT PHARMACEUTICALS, INC as Guarantor UNDERLEASE relating... (Filed With SEC on February 29, 2016)

OFFICE SUBLEASE (Filed With SEC on February 29, 2016)

INTERCEPT PHARMACEUTICALS, INC. NON-EMPLOYEEDIRECTOR COMPENSATION POLICY (Filed With SEC on February 17, 2016)

DATED: October 13, 2014 (1) INTERCEPT PHARMACEUTICALS, INC. and (2) LISA BRIGHT MORRISON ___________________________________________ SERVICEAGREEMENT UK EMPLOYEE... (Filed With SEC on May 11, 2015)

INTERCEPT PHARMACEUTICALS, INC. (a Delaware corporation) 1,200,000 Shares of Common Stock UNDERWRITING AGREEMENT (Filed With SEC on April 2, 2015)

MERCK SHARP &DOHME LIMITED (1) and INTERCEPT PHARMACEUTICALS,INC. (2) Underlease relating to Part 1st Floor, 2 St PancrasSquare London 80 Guildhall Street, Bury St Edmunds,... (Filed With SEC on February 25, 2015)

INTERCEPT PHARMACEUTICALS, INC. (a Delaware corporation) 1,000,000 Shares of Common Stock UNDERWRITING AGREEMENT (Filed With SEC on February 6, 2015)

INTERCEPT PHARMACEUTICALS, INC. NON-EMPLOYEEDIRECTOR COMPENSATION POLICY (Filed With SEC on May 9, 2014)

EMPLOYMENT AGREEMENT (Filed With SEC on May 9, 2014)

INTERCEPT PHARMACEUTICALS, INC. Restricted Stock Award Grant Notice forDirectors Restricted Stock Award Grant under the Company’s 2012 Equity Incentive Plan (Filed With SEC on May 9, 2014)

INTERCEPT PHARMACEUTICALS, INC. Restricted Stock Award Grant Notice forEmployees and Consultants Restricted Stock Award Grant under the Company’s 2012 Equity Incentive Plan (Filed With SEC on May 9, 2014)

OFFICE SPACE LEASE BETWEEN THEIRVINE COMPANY LLC AND InterceptPharmaceuticals, Inc. (Filed With SEC on May 7, 2014)

INTERCEPTPHARMACEUTICALS, INC.4 (a Delawarecorporation) 1,000,000Shares of Common Stock UNDERWRITINGAGREEMENT (Filed With SEC on April 4, 2014)

*** OMITTED AND FILED SEPARATELY WITHTHE SECURITIES AND EXCHANGE COMMISSION CONFIDENTIAL TREATMENT REQUESTED UNDER17 C.F.R. SECTION 240.24b-2 AMENDMENT N°4 TO PRODUCT RESEARCH,... (Filed With SEC on January 2, 2014)

*** OMITTED AND FILED SEPARATELY WITHTHE SECURITIES AND EXCHANGE COMMISSION CONFIDENTIAL TREATMENT REQUESTED UNDER17 C.F.R. SECTION 240.24b-2 AMENDMENT NO. 4 TO CONSULTING AND... (Filed With SEC on January 2, 2014)

*** OMITTED AND FILED SEPARATELY WITHTHE SECURITIES AND EXCHANGE COMMISSION CONFIDENTIAL TREATMENT REQUESTED UNDER17 C.F.R. SECTION 240.24b-2 AMENDMENT NO. 4 TO RESEARCH AND... (Filed With SEC on January 2, 2014)

SECOND AMENDMENT (Filed With SEC on December 2, 2013)

JAMESTOWN 450 WEST 15TH STREET,L.P., (Filed With SEC on October 21, 2013)

INTERCEPTPHARMACEUTICALS, INC. (a Delawarecorporation) [________]Shares of Common Stock UNDERWRITINGAGREEMENT (Filed With SEC on October 8, 2013)

INTERCEPT PHARMACEUTICALS,INC. (a Delawarecorporation) Shares of CommonStock UNDERWRITINGAGREEMENT (Filed With SEC on June 14, 2013)

EMPLOYMENTAGREEMENT (Filed With SEC on May 14, 2013)

AMENDEDAND RESTATED EMPLOYMENT AGREEMENT (Filed With SEC on May 14, 2013)

EMPLOYMENTAGREEMENT (Filed With SEC on May 14, 2013)

CONSULTING AGREEMENT (Filed With SEC on May 14, 2013)

INTERCEPTPHARMACEUTICALS, INC. 2013 NON-EMPLOYEEDIRECTOR COMPENSATION POLICY (Filed With SEC on May 13, 2013)

AMENDMENT NO. 1 TO SPONSORED RESEARCH AGREEMENT (Filed With SEC on April 30, 2013)

AMENDMENT NO. 1 TO CONSULTING AND IP AGREEMENT (Filed With SEC on April 30, 2013)

AMENDMENT TO EMPLOYMENT AGREEMENT (Filed With SEC on April 15, 2013)

EMPLOYMENTAGREEMENT (Filed With SEC on April 1, 2013)

INVENTION, NON-DISCLOSURE, AND NON-SOLICITATIONAGREEMENT (Filed With SEC on April 1, 2013)

FIRST AMENDMENT (Filed With SEC on March 22, 2013)

AMENDMENT N°2 TO PRODUCT RESEARCH, DEVELOPMENT, LICENSE AND COMMERCIALIZATION AGREEMENT (this “Amendment”) (Filed With SEC on February 22, 2013)

AMENDMENT NO. 2 TO CONSULTING AND INTELLECTUAL PROPERTY(“IP”) AGREEMENT (Filed With SEC on February 22, 2013)

AMENDMENT NO. 2 TO RESEARCH AND DEVELOPMENT AGREEMENT (Filed With SEC on February 22, 2013)

INTERCEPT PHARMACEUTICALS, INC. (a Delaware corporation) [l]Shares of Common Stock UNDERWRITING AGREEMENT (Filed With SEC on September 27, 2012)

Additional abbreviations may also be used though notin the above list. (Filed With SEC on September 27, 2012)

INTERCEPT PHARMACEUTICALS, INC. 2012 EQUITY INCENTIVE PLAN (Filed With SEC on September 27, 2012)

INTERCEPT PHARMACEUTICALS, INC. Stock Option Grant Notice for Directors Stock Option Grant under the 2012 Equity Incentive Plan (Filed With SEC on September 27, 2012)

INTERCEPT PHARMACEUTICALS, INC. Stock Option Grant Notice for Employeesand Consultants Stock Option Grant under the 2012 Equity Incentive Plan (Filed With SEC on September 27, 2012)

INTERCEPT PHARMACEUTICALS, INC. Restricted Stock Unit Award Grant Noticefor Directors Restricted Stock Unit Award Grant underthe Company’s 2012 EquityIncentive Plan (Filed With SEC on September 27, 2012)

INTERCEPT PHARMACEUTICALS, INC. Restricted Stock Unit Award Grant Noticefor Employees and Consultants Restricted Stock Unit Award Grant underthe Company’s 2012 EquityIncentive... (Filed With SEC on September 27, 2012)

INTERCEPTPHARMACEUTICALS, INC. NON-EMPLOYEEDIRECTOR COMPENSATION POLICY (Filed With SEC on September 27, 2012)

LICENSE AGREEMENT (Filed With SEC on September 27, 2012)

PRODUCT RESEARCH, DEVELOPMENT, LICENSE AND COMMERCIALIZATION AGREEMENT by and between LES LABORATOIRES SERVIER and INSTITUT DE RECHERCHES SERVIER on the one hand AND INTERCEPT... (Filed With SEC on September 27, 2012)

CONSULTING AND INTELLECTUAL PROPERTY(“IP”) AGREEMENT (Filed With SEC on September 27, 2012)

RESEARCH AND DEVELOPMENT AGREEMENT (Filed With SEC on September 27, 2012)

CONSULTINGAGREEMENT (Filed With SEC on September 27, 2012)

INTERCEPTPHARMACEUTICALS, INC. THIRD amendedand restated stockholders agreement (Filed With SEC on September 4, 2012)

THIS WARRANT AND THESHARES OF COMMON STOCK ISSUED UPON ITS EXERCISE ARE SUBJECT TO THE RESTRICTIONS ON TRANSFERSET FORTH IN SECTION 5 OF THIS WARRANT (Filed With SEC on September 4, 2012)

THIS WARRANT AND THESHARES OF COMMON STOCK ISSUED UPON ITS EXERCISE ARE SUBJECTTO THE RESTRICTIONS ON TRANSFERSET FORTH IN SECTION 5 OF THIS WARRANT (Filed With SEC on September 4, 2012)

THIS WARRANT AND THE SHARESOF COMMON STOCK ISSUED UPON ITS EXERCISE ARE SUBJECT TO THE RESTRICTIONS ON TRANSFER SET FORTH IN SECTION 5 OF THIS WARRANT (Filed With SEC on September 4, 2012)

INTERCEPT PHARMACEUTICALS, INC. Common Stock Purchase Warrant (“ClassA”) (Void after May 4, 2014) (Filed With SEC on September 4, 2012)

THISWARRANT AND THE SHARES OF COMMON STOCK ISSUED UPON ITS EXERCISEARE SUBJECT TO THE RESTRICTIONS ON TRANSFERSET FORTH IN SECTION 5 OF THIS WARRANT (Filed With SEC on September 4, 2012)

THIS WARRANT AND THE SHARES OF COMMONSTOCK ISSUED UPON ITS EXERCISE ARE SUBJECT TO THE RESTRICTIONS ON TRANSFER SET FORTH IN SECTION 5 OF THIS WARRANT AND TO CERTAINTRANSFER... (Filed With SEC on September 4, 2012)

INTERCEPT PHARMACEUTICALS, INC. Form of Common Stock Purchase Warrant (Void after January 20, 2015) (Filed With SEC on September 4, 2012)

INTERCEPT PHARMACEUTICALS, INC. AMENDED AND RESTATED 2003 STOCK INCENTIVE PLAN (amended and restated as of June 11, 2008,and further amended on January 19, 2010) (Filed With SEC on September 4, 2012)

INTERCEPT PHARMACEUTICALS, INC. Nonstatutory Stock Option Agreement Granted Under 2003 Stock Incentive Plan (Filed With SEC on September 4, 2012)

INTERCEPT PHARMACEUTICALS, INC. Incentive Stock Option Agreement Granted Under 2003 Stock Incentive Plan (Filed With SEC on September 4, 2012)

AMENDMENT TO INTERCEPT PHAMACUETICALS, INC. 2003 AMENDED AND RESTATED STOCK INCENTIVEPLAN (Filed With SEC on September 4, 2012)

EMPLOYMENT AGREEMENT (Filed With SEC on September 4, 2012)

NON-COMPETITION AND NON-SOLICITATIONAGREEMENT (Filed With SEC on September 4, 2012)

INVENTION, NON-DISCLOSURE, AND NON-SOLICITATIONAGREEMENT (Filed With SEC on September 4, 2012)

EMPLOYMENT AGREEMENT (Filed With SEC on September 4, 2012)

INVENTION, NON-DISCLOSURE, AND NON-SOLICITATION AGREEMENT (Filed With SEC on September 4, 2012)

EMPLOYMENT AGREEMENT (Filed With SEC on September 4, 2012)

INVENTION, NON-DISCLOSURE,AND NON-SOLICITATION AGREEMENT (Filed With SEC on September 4, 2012)

FORM OF INDEMNIFICATION AGREEMENT (Filed With SEC on September 4, 2012)

GUARANTY (Filed With SEC on September 4, 2012)

OFFICE SPACE LEASE BETWEEN 4350 LA JOLLA VILLAGE LLC AND INTERCEPT PHARMACEUTICALS, INC. (Filed With SEC on September 4, 2012)

LICENSE AGREEMENT (Filed With SEC on September 4, 2012)

PRODUCT RESEARCH, DEVELOPMENT, LICENSE AND COMMERCIALIZATION AGREEMENT by and between LES LABORATOIRES SERVIER and INSTITUT DE RECHERCHES SERVIER on the one hand AND INTERCEPT... (Filed With SEC on September 4, 2012)

AMENDMENT N°1 TO PRODUCT RESEARCH, DEVELOPMENT, LICENSE AND COMMERCIALIZATION AGREEMENT (Filed With SEC on September 4, 2012)

PUBLIC HEALTH SERVICE COOPERATIVE RESEARCH AND DEVELOPMENTAGREEMENT FOR EXTRAMURAL-PHS CLINICAL RESEARCH (Filed With SEC on September 4, 2012)

SPONSORED RESEARCH AGREEMENT (Filed With SEC on September 4, 2012)

CONSULTING AND INTELLECTUAL PROPERTY (“IP”)AGREEMENT (Filed With SEC on September 4, 2012)

AMENDMENT N°1 TO CONSULTING AND INTELLECTUAL PROPERTY(“IP”) AGREEMENT (Filed With SEC on September 4, 2012)

CONSULTING AND IP AGREEMENT (Filed With SEC on September 4, 2012)

RESEARCH AND DEVELOPMENT AGREEMENT (Filed With SEC on September 4, 2012)

AMENDMENT N°1 TO RESEARCH AND DEVELOPMENT AGREEMENT (Filed With SEC on September 4, 2012)

WITNESSETH (Filed With SEC on September 4, 2012)

AMENDMENT #1 To The MASTER LABORATORY SERVICESAGREEMENT (Filed With SEC on September 4, 2012)

INTERCEPT PHARMACEUTICALS, INC. SERIES C CONVERTIBLE PREFERRED STOCK PURCHASEAGREEMENT* Dated as of August 9, 2012 (Filed With SEC on September 4, 2012)

Category

Industry

Companies

Contracts

INTERCEPT PHARMACEUTICALS, INC. Contracts & Agreements